Scientists have discovered the mechanism by which Redsyvir inhibits the new coronavirus

Recently, the reporter learned from Beijing Concord Hospital, the party secretary of the hospital Zhang Liyang team in cooperation with the Chinese Academy of Sciences Shanghai Institute of Pharmacy Xu Huaqiang, Xu Yechun task force and Zhejiang University School of Basic Medicine Zhang Yan task force after 46 days of day and night struggle, the first analysis of the new coronary pneumonia virus important drug target RNA replication enzyme and inhibitor Rui Remdesivir's high-resolution cryoscopic structure, which describes the pattern of RNA replication enzyme binding to RNA, and The mechanism by which Redsivir inhibits RNA extension, provides a theoretical mechanism and structural basis for the development of anti-neo-coronaviral drugs and broad-spectrum antiviral drugs based on viral gene replication enzymes. The paper was published online in Science.
severe neo-coronavirus infection often causes multi-organ dysfunction in patients, including acute respiratory distress syndrome, acute cardiomyopathy, acute kidney injury, dispersal blood vessel clotting, etc., which is extremely difficult to treat.
, although multidisciplinary joint treatment has achieved some results, the death rate of patients with critically ill neo-coronary pneumonia is still very high. Faced with the difficulty of not yet treating specific drugs, there is an urgent need to understand the efficacy and potential mechanisms of action of antiviral drugs such as Redsivir in patients infected with neo-coronary pneumonia.
, the team found that the new coronary pneumonia virus mainly infects human cells through the mucous membrane system, and that a large number of copies of the virus after infection require rapid synthesis of its genetic material RNA. The core component of the process, RNA replication enzymes, is a core component of coronavirus replication. Several nucleoside drugs currently undergoing clinical trials, including Redsivir, are targeted RNA replication enzymes.
the efficacy of Redsiway, the results of clinical trials at home and abroad are not consistent. Zhang Liyan team designed the potential RNA binding sequence of the new coronavirus polymerase, and for the first time used in-body biotransviral experiments to establish the determination method of the activity of the new coronavirus replication enzyme, through the drug suppression test revealed that the form of Redsivir tripolyphosphate is the final active small molecular form, Redsyvir tripolyphosphate molecules in introphysic data inhibition of Rdrp, providing a theoretical basis for clinical trials.
To further elaborate the fine mechanism of antiviral drugs such as Redsivir, the team also successfully analyzed the separate structure of the new coronary pneumonia virus RNA replication enzyme 2.8? resolution and the frozen electroscope structure that binds RNA and inhibitor Redsyvir to a resolution of 2.5 E.
In addition, the study also described how Redsyvir entered the virus replication activity center and inserted the virus genome at a cost, thereby inhibiting viral replication, and structurally explained Redsyviral's antiviral mechanism, providing a structural basis for other potential antiviral drug development currently under study.
, however, the researchers say that in the evaluation of Redsyway's clinical efficacy, rigorous clinical trials are still needed to give a final answer. (Source: Zhang Siwei, China Science Journal)
relevant paper information: